Coronary Artery Disease
Conditions
Interventions
Group 2:5%Glucose water
Sponsors
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Agreement for primary PCI strategy; 2. ST elevation in ECG of 0.1mV in 2 or more limbs, or 0.2mV in ST elevation of 2 or more adjacent thoracic leads; or a newly developed complete left (or right) bundle branch block; 3. Patients with ST E M I with persistent ischemic chest pain for 30min and 12 hours or the onset time of 12-24 hours, such as still progressive ischemic chest pain or hemodynamic instability, and continuous S T segment elevation; 4. Consent to participate in this clinical trial and signed a written informed consent before surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with cardiogenic shock, severe heart failure (Killip III and IV), malignant ventricular arrhythmia or mechanical complications; 2. Get coenzyme I or other myocardial nutrients (e.g. trammetazidine, coenzyme Q10, phosphate creatine, ranolazine) 30 days before the start of the experiment or during the hospitalization; 3. History of trauma within 2 months, including traumatic CPR or prolonged CPR (10min) CPR, or major surgical surgery; history of head trauma within 6 months; 4. Uncontrolled hypertension patients (systolic blood pressure 180mmHg and/or diastolic blood pressure 110mmHg); 5. Patients with a previous history of myocardial infarction, PCI, or coronary artery bypass grafting (CABG); 6. History of severe liver and renal dysfunction (AST/ALT above 3 times the upper normal value; creatinine 225 umol/L); 7. Patients with severe diseases, such as malignancy, lymphoma, cirrhosis, and HIV-positive patients, whose expected survival life is <1 year; 8. A history of active bleeding, intracranial hemorrhage, a history of major surgery or trauma within 1 month, and a history of ischemic stroke or transient ischemic attack (TIA) within 6 months; 9. Patients with multiple lesions planned to intervene in non-target vessels within 7 days (concurrent or secondary); 10. CABG within 1 month after screening; 11. Women born in pregnancy or preparation for pregnancy or lactation; 12. Those known to be allergic to coenzyme I injection and its ingredients or have serious adverse reactions; 13. Those who have participated in other clinical trials within 3 months before the trial; 14. Judging by the investigator, the patient cannot complete the study or comply with the requirements of the study; 15. Reinfarction in the same area as in the previous sites; 16. Participating in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Ventricular Ejection Fractions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular and cerebrovascular events, MACCE;Systemic vascular resistance, SVR;Cardiac output, CO;Stroke volume, SV;Left ventricular stroke work index; | — |
Countries
China
Contacts
Public ContactLikun Ma
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Outcome results
None listed